Adults 18 to 70, female only, with Overactive Bladder Syndrome. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline in Micturition Episode Components (Micturition, Incontinence, and Urgency) Per 24 Hours.Primary· Baseline, Weeks 2, and 8
Subjects were asked to record all micturition episode components into a daily electronic diary during the 3 to 7 days prior to each scheduled clinic visit.
Number of Micturition Episodes per 24 hours
Group
Value
95% CI
Week 2 (Placebo)
-0.8
± 1.97
Week 8 (V117957)
-0.8
± 2.32
Number of Incontinence Episodes per 24 hours
Group
Value
95% CI
Week 2 (Placebo)
-0.2
± 0.60
Week 8 (V117957)
-0.4
± 0.81
Number of Urgency Episodes per 24 hours
Group
Value
95% CI
Week 2 (Placebo)
-0.5
± 1.20
Week 8 (V117957)
-0.5
± 2.07
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events (AEs) were reported starting from the time informed consent for study participation was provided up to 16 weeks. All-cause mortality and serious adverse events were reported from the start of study participation up to 30 days after last study drug dose (approximately 20 weeks)..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imbrium Therapeutics
Last refreshed: 26 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06024642.